Nifty 17196.7 (-1.18%)
Sensex 57696.46 (-1.31%)
Nifty Bank 36197.15 (-0.85%)
Nifty IT 35848.05 (-0.86%)
Nifty Financial Services 17779.5 (-1.13%)
Adani Ports 737.45 (-0.22%)
Asian Paints 3110.45 (-2.21%)
Axis Bank 673.00 (-0.46%)
B P C L 385.90 (1.86%)
Bajaj Auto 3287.85 (-1.22%)
Bajaj Finance 7069.25 (-1.55%)
Bajaj Finserv 17488.70 (-1.52%)
Bharti Airtel 718.35 (-1.94%)
Britannia Inds. 3553.75 (-0.69%)
Cipla 912.05 (-1.00%)
Coal India 159.75 (0.28%)
Divis Lab. 4757.05 (-0.42%)
Dr Reddys Labs 4596.50 (-1.42%)
Eicher Motors 2455.55 (0.16%)
Grasim Inds 1703.90 (-1.16%)
H D F C 2771.65 (-1.29%)
HCL Technologies 1171.40 (-1.12%)
HDFC Bank 1513.55 (-0.80%)
HDFC Life Insur. 690.95 (-2.03%)
Hero Motocorp 2462.45 (-0.41%)
Hind. Unilever 2343.65 (-1.66%)
Hindalco Inds. 424.65 (-1.72%)
I O C L 122.20 (1.28%)
ICICI Bank 716.30 (-0.84%)
IndusInd Bank 951.15 (0.59%)
Infosys 1735.55 (-0.73%)
ITC 221.65 (-1.69%)
JSW Steel 644.55 (-0.34%)
Kotak Mah. Bank 1914.20 (-2.55%)
Larsen & Toubro 1801.25 (0.67%)
M & M 836.95 (-1.48%)
Maruti Suzuki 7208.70 (-1.59%)
Nestle India 19321.35 (-0.93%)
NTPC 127.00 (-1.32%)
O N G C 145.90 (1.32%)
Power Grid Corpn 206.10 (-3.92%)
Reliance Industr 2408.25 (-3.00%)
SBI Life Insuran 1165.95 (-1.86%)
Shree Cement 25914.05 (-1.43%)
St Bk of India 473.15 (-0.81%)
Sun Pharma.Inds. 751.80 (-1.89%)
Tata Consumer 774.30 (0.14%)
Tata Motors 480.10 (0.21%)
Tata Steel 1118.00 (0.50%)
TCS 3640.45 (-0.07%)
Tech Mahindra 1593.30 (-2.23%)
Titan Company 2369.25 (-0.72%)
UltraTech Cem. 7332.45 (0.13%)
UPL 712.75 (2.08%)
Wipro 640.75 (-0.94%)

Cyrus Poonawala: A horse enthusiast who became the vaccine king of the world

Cyrus Poonawala: A horse enthusiast who became the vaccine king of the world 
by 5paisa Research Team 22/11/2021

Cyrus Poonawala is known for his flamboyant lifestyle has a net worth of USD 18 billion.

Serum institute which was founded in Pune in 1966 went on to become World’s largest vaccine maker. And in turn made its founder a billionaire, the 5th Richest Indian in 2021 and a regular in the World’s billionaires list.

"We reach more children than Coca-Cola and Pepsi can ever hope to."- CYRUS POONAWALLA 

Today it is estimated that about 65% of the children in the world across 170 countries receive at least one vaccine manufactured by Serum Institute. Such is the positive impact to mankind by the vaccine manufacturer.

Cyrus Poonawala is the chairman and managing director of the Cyrus Poonawalla Group. Born to a horse breeder in Pune, Cyrus, founded SII in 1966 as a sideline to his 81-hectare (200-acre) thoroughbred racehorse stables Poonawalla Stud. Serum from purified horse blood was used in the production of early vaccines for diphtheria, tetanus, and scarlet fever. Today, this billionaire and a horse enthusiast played a significant role to help the world combat many life-threatening diseases and the deadly Coronavirus.

Serum Institute produces over 1.5 billion doses annually of a variety of vaccines, including measles, polio and flu. Serum has multiple Covid-19 vaccine partnerships and has launched Covishield, the vaccine developed by AstraZeneca and Oxford University.

Poonawala is a regular on Forbes Billionaires since 2007. In March 2017, he was listed as India’s number 7 on the richest billionaire's list and 159th in the world, with a net worth of USD 8.1 billion.

Poonawalla was listed at 170th on the Forbes billionaires’ list for 2018, with a net worth estimated to be USD 9.1 billion which was valued at USD 9.5 billion in 2019.

He secured the 165th spot in 2020 with a net worth of USD 8.2 billion, the 6th richest Indian that year.

The Serum boss was listed at 169th on the Forbes billionaire’s list for the current year and 5th richest Indian with a net worth of USD 12.7 billion.

In October India became the third country to have administered 1 billion Covid jabs. The country achieved this feat in 278 days since the first vaccine, which was given on January 16, 2021, with more than 80% doses of Covishield.

The current net worth of the “Vaccine King“ is USD 18.1 billion. With every dose of Covishield administered a life is saved and a small fortune is made Cyrus Poonawala.

Open Demat Account

Enter First Name & Last Name
Enter Mobile Number
Enter correct otp
Please enter referal code
Start investing in just 5 mins
Free Demat account, No conditions apply
  • 0%* Brokerage
  • Flat ₹20 per order
Next Article

Superstar stocks for tomorrow!

Superstar stocks for tomorrow!
by 5paisa Research Team 22/11/2021

Looking for stocks that could deliver good returns till tomorrow, here are the superstar stocks for tomorrow selected on a three-factor model.

Many of the time market participants see a stock opening with a gap-up and wish they should have bought this superstar stock a day before to take advantage of the gap-up move. To fulfil this wish, we have come out with a unique system, which would help us to get the list of candidates that can be probable superstar stocks for tomorrow.

The superstock stocks for tomorrow selected are based on a three-factor prudent model. The first important factor for this model is price, the second key factor is the pattern, and last but not least is the combination of momentum with volume. If a stock passes all these filters it would flash in our system and as a result, it will help traders to spot the superstar stocks for tomorrow at the right time!

Here are the superstar stocks for tomorrow.

Godrej Industries: Despite market bleeding on Monday, the stock is trading rock solid by being 1.23% up. Initially, the stock fell but huge buying was seen at lower levels. The outperformance against broader indices today suggests the good strength of the stock for coming days. It witnessed above average volumes and the RSI is in the bullish territory and the stock looks attractive for coming day.

Dabur: Dabur is trading flat despite all the stocks are heavily bleeding on Monday. The stock of Dabur was rising throughout the day before correcting a little. The RSI going at 50 despite poor market indicates strength of the stock. Above average volumes were recorded today. Dabur is a strong candidate for gap-up if the market remains positive tomorrow given the fact that Dabur traded strong today.

Open Demat Account

Enter First Name & Last Name
Enter Mobile Number
Enter correct otp
Please enter referal code
Start investing in just 5 mins
Free Demat account, No conditions apply
  • 0%* Brokerage
  • Flat ₹20 per order
Next Article

Multibagger Alert: This speciality chemical company has given investors a return of 231% in the past year

Multibagger Alert: This speciality chemical company has given investors a return of 231% in the past year
by 5paisa Research Team 22/11/2021

On a YTD basis, the stock has given a return of 241%.

Leading manufacturer of aliphatic amines and speciality chemicals in India, Balaji Amines Limited has given investors stellar returns of 231.4% over the last year. The share price stood at Rs 953.75 on November 18, 2020, and since then, the stock has more than tripled investor wealth.

Balaji Amines manufactures, sells and exports methylamines, ethylamine and derivatives of speciality chemicals and pharma excipients in India. The firm serves pharmaceuticals, agrochemicals, refineries, paints, water treatment chemicals, dyes, coatings, polymers, textiles, personal and home care, animal nutrition etc.

On a standalone basis in Q2, Balaji Amines reported robust revenue of Rs 435.12 crore, which was up 54.92% YoY driven by higher realizations. Operating profit came 41.31% higher YoY to Rs 102.06 crore. Operating margins contracted to 22.49% from 24.85% due to high raw material prices and increased power and fuel cost. PAT was reported at Rs 69.59 crore was up 46.01% YoY. The management of the company expects better H2FY22 performance and have guided for 8-10% volume growth in the amine business of the company into consolidated revenue guidance of Rs 1800-1850 crore in FY22.

The global amines industry is expected to reach US$ 20.8 billion by 2025, registering a CAGR of 3.6%. The oligopolistic nature of the industry leaves a country with just a handful of producers catering to the majority of the demand in the region. The increasing trend of industrialization and expanding manufacturing sector, coupled with factors such as growing population and rapid urbanization are likely to have a positive impact on the demand for amines in the years to come.

Moreover, due to stricter environmental norms, tighter financing, and consolidation, the structure of China’s chemical industry is changing causing uncertainty for international players that source chemicals from China. This has created opportunities for Indian chemical companies to ensure uninterrupted supply. This coupled with stringent policies in regulatory norms, slow economic growth and the rising cost of labour across the globe has improved the sales volume of domestic chemical manufactures such as Balaji Amines.

At 1.15 pm on Monday, the stock is trading at Rs 3040.85, down by 3.79% or Rs 119.90 per share on BSE. The 52-week high of the scrip is recorded at Rs 5,220 and the 52-week low at Rs 850 on the BSE.

Open Demat Account

Enter First Name & Last Name
Enter Mobile Number
Enter correct otp
Please enter referal code
Start investing in just 5 mins
Free Demat account, No conditions apply
  • 0%* Brokerage
  • Flat ₹20 per order
Next Article

HFCL trades volatile after bagging order worth Rs 412.90 crore

HFCL trades volatile after bagging order worth Rs 412.90 crore
by 5paisa Research Team 22/11/2021

Shares of HFCL gained from the previous close of Rs 72.85 to Rs 74.70 after the news break but slipped to Rs 69.85 in a matter of time.

In today’s morning trading session HFCL rose 2.53% to Rs 74.70 owing to this news that the company secured purchase orders aggregating to Rs 412.90 crore from one of the leading Private Telecom Operators of the Country for the supply of Optical Fibre Cables (OFC). The order will be executed by March 2022.

Company and its client base

HFCL is a midcap diverse telecom infrastructure enabler with active interest spanning telecom infrastructure development, system integration, and manufacture and supply of high-end telecom equipment, Optical Fiber and Optic Fiber Cable (OFC).

Company's client base includes Jio, Tata, Airtel, Vodafone, Nokia, L&T, Orange, BSNL, BBNL, TCIL, BPCL, IOL, Railtel, HPCL, PGC, GAIL, Saudi Railways and others.

As of September 2021, the company had an order book of Rs 5,822 crore out of which Rs 4,500 crore worth of orders are where BSNL is the implementing agency. The order book broadly consists of defence projects (57%), optical fibre cable (14%), orders from RJIL (14%) BharatNet (7%) and others (8%).

Financials

HFCL consolidated revenue for the quarter Q2FY22 came in at Rs 1,126 crore as against Rs 1,068 crore in the corresponding quarter last year, registering a 5.62% YoY increase.

The EBITDA for the quarter grew by 25.99% YoY to Rs 173.33 crore as against Rs 137.5 crore in the corresponding quarter last year, with a corresponding margin expansion of 240 bps. EBITDA margin for the quarter stood at 15.44%.

The PAT for the quarter came in at Rs 86.1 crore as against Rs 53.3 crore in the corresponding quarter last year, a YoY increase of 61.18%.

Market opportunity: Rs 4-5 lakh crore in 5G alone; Rs 5000 crore in Defence, Rs 85000 crore in Railways in the next 4-5 years. There is an immense demand for fibre optic cables, telecom and networking products across the world followed by expansion of 4G and evolution of 5G network.

At 2.15 PM, HFCL was trading at Rs 69.70, 4.30% down for the day.

Open Demat Account

Enter First Name & Last Name
Enter Mobile Number
Enter correct otp
Please enter referal code
Start investing in just 5 mins
Free Demat account, No conditions apply
  • 0%* Brokerage
  • Flat ₹20 per order
Next Article

Heranba Industries initiates commercial production at its Vapi unit

Heranba Industries initiates commercial production at its Vapi unit
by 5paisa Research Team 22/11/2021

This new unit which is located at Vapi, shall have a production capacity of 1200 MTPA and is expected to generate annual revenue of Rs 100 crore.

Heranba Industries Limited, an Indian agrochemical company that manufactures synthetic pyrethroids and its intermediates, announced the beginning of commercial production at its new Unit –IV.

Located at Vapi, this new unit shall have a production capacity of 1200 MTPA. It will not require any capital expenditure in near future and is expected to generate annual revenue of Rs 100 crore. This development is aligned with Heranba’s commitment and promises towards fostering sustainable growth while also creating job opportunities in the region.

Speaking about this development, the company’s managing director, R K Shetty said that the commencement of production shall result in additional revenue generation for the company. And that it is a recognition of the company’s established track record, healthy accruals and resiliency of the business model. He further said that in order to achieve significant margin expansion, the company is dedicated towards accelerating revenue growth and enhancing its productivity.

Coming to financial performance, in Q2FY22, Heranba’s net revenue grew by 1.22% YoY to Rs 353.44 crore. The PBIDT (ex OI) went up 9.59% YoY to Rs 61.18 crore. The PBIDT (ex OI) margin expanded by 132 bps to 17.31%. This growth came on the back of reduced expenses. The company’s net profit went up by 20.9% YoY to Rs 45.52 crore, whereas its corresponding margin expanded by 211 bps to 12.91%.

Going forward, the company aims to venture into the highly regulated markets of the USA and Europe, strengthen its R&D facility, and enhance production capacities as well as formulation and technicals in the international markets.

At 3.25 pm, the share price of Heranba Industries Limited was trading at Rs 655.55, which was a decrease of 2.27% from the previous week’s closing price of Rs 670.8 on BSE.

Open Demat Account

Enter First Name & Last Name
Enter Mobile Number
Enter correct otp
Please enter referal code
Start investing in just 5 mins
Free Demat account, No conditions apply
  • 0%* Brokerage
  • Flat ₹20 per order
Next Article

Mutual funds have been purchasing these mid-cap stocks. Did you buy any?

by 5paisa Research Team 22/11/2021

Domestic mutual funds have become very significant players in the local stock market over the last few years given the rush of local liquidity. In fact, MFs are now almost as strong as foreign portfolio investors (FPIs) or foreign institutional investors (FIIs), which have been the driver of local bourses historically.

Indeed, the bull run of the past few months is largely attributed to the flow of cash into domestic mutual funds, which have pumped in a massive amount of money into the stock market.

However, Indian stock indices have been seeing a rush of money towards large cap stocks as investors, anticipating a correction, looked for safer investments rather than make riskier bets.

Although most local fund managers have been voicing concerns about valuations, quarterly shareholding data shows they pushed up their holding in over 200 listed companies. Of those, they increased their stake by two percentage points or more in around 18% of the companies.

In particular, they hiked stake in as many as 129 companies (as against 89 companies for FIIs) that have a valuation of $1 billion or more last quarter. Of these 129 companies, 67—or a little more than half—were mid-cap companies. In comparison, FIIs had increased their stake in 57 mid-cap stocks with a market valuation of Rs 5,000-20,000 crore last quarter. This shows local fund managers were more bullish about mid-cap counters than offshore investors.

Mutual fund managers were bullish on mid-cap banks, healthcare companies and drugmakers, NBFCs, automobile and auto component makers, real estate developers, and infrastructure companies.

Some of these are the same as the sectors backed by FIIs last quarter—financial services, construction, engineering and industrial.

Top mid-caps that saw MF buying

If we look at the pack of mid-caps with market cap between Rs 5,000 crore and Rs 20,000 crore, then MFs pushed up their stake in Indian Bank, Thermax, Prestige Estates, GR Infraprojects, Phoenix Mills, Gujarat State Petronet, Sundram Fasteners, Manappuram Finance, Sheela Foam and WABCO India.

Among others where MFs bought shares were Radico Khaitan, Poonawalla Fincorp, Century Plyboards, Timken India, Apollo Tyres, Birlasoft, Suven Pharma, Zydus Wellness, JB Chemicals, Cyient, KEC International, Bajaj Electricals, BASF India, RBL Bank and Narayana Hrudayalaya.

GR Infraprojects, Bajaj Electricals and Narayana Hrudayalaya were mid-cap stocks that figured among the buy calls of both FIIs and domestic MFs.

Further lower down the order were stocks like, City Union Bank, Amber Enterprises, Sterlite Tech, Birla Corp, V-Guard, Mahindra CIE, KIMS, Blue Star, Ratnamani Metals and MCX.

Meanwhile, in at least 13 mid-caps, mutual funds bought an additional stake of 2% or more last quarter. This pack includes GR Infraprojects, Can Fin Homes, MCX, Tatva Chintan Pharma, KIMS Hospitals, Apollo Tyres, Birlasoft, Manappuram Finance, Chalet Hotels, J B Chemicals, RBL Bank, Mahindra CIE Automotive and Indiabulls Real Estate.

GR Infraprojects and Indiabulls Real Estate had also significant buying by FIIs.

Open Demat Account

Enter First Name & Last Name
Enter Mobile Number
Enter correct otp
Please enter referal code
Start investing in just 5 mins
Free Demat account, No conditions apply
  • 0%* Brokerage
  • Flat ₹20 per order